By: IPP Bureau
Last updated : September 26, 2024 7:15 am
The Notes shall not be offered or sold in India
Biocon Biologics Global, incorporated under the laws of the United Kingdom and being a subsidiary of Biocon Biologics UK Limited, which is a subsidiary of Biocon Biologics Limited and a step-down subsidiary of the Biocon Limited, subject to market conditions and due exigencies, is proposing to offer senior secured notes (the "Notes").
A preliminary offering memorandum dated September 23, 2024 has been prepared which shall be made available to the prospective investors and shall be submitted with the Singapore Exchange Limited (SGX). The Notes shall not be offered or sold in India.
The Notes are proposed to be irrevocably and unconditionally guaranteed on behalf of the Issuer by, among others, Biocon Biologics, being a material subsidiary of the Company and secured by, among others, a pledge over certain shares held by Biocon Biologics in Biosimilars Newco. Limited, being a subsidiary of Biocon Biologics.
The pricing of the Notes, including the aggregate principal amount, the issue price and the interest rate, shall be determined in accordance with international market practices by the joint global coordinators and joint lead managers appointed by the Issuer.